View Item 

Show simple item record

Aldosterone blockade in post‐acute myocardial infarction heart failure
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorFerrari, Robertoen_US
dc.contributor.authorGheorghiade, Mihaien_US
dc.contributor.authorvan Veldhuisen, Dirk J.en_US
dc.contributor.authorKrum, Henryen_US
dc.contributor.authorMcMurray, Johnen_US
dc.contributor.authorLopez‐sendon, Joseen_US
dc.date.accessioned2012-03-16T15:54:32Z
dc.date.available2012-03-16T15:54:32Z
dc.date.issued2006-10en_US
dc.identifier.citationPitt, Bertram; Ferrari, Roberto; Gheorghiade, Mihai; van Veldhuisen, Dirk J.; Krum, Henry; McMurray, John; Lopez‐sendon, Jose (2006). "Aldosterone blockade in postâ acute myocardial infarction heart failure." Clinical Cardiology 29(10): 434-438. <http://hdl.handle.net/2027.42/90106>en_US
dc.identifier.issn0160-9289en_US
dc.identifier.issn1932-8737en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90106
dc.description.abstractDevelopment of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in‐hospital pharmacologic management of AMI with LVSD and/or HF is presented.en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherEPHESUSen_US
dc.subject.otherEplerenoneen_US
dc.subject.otherLeft Ventricular Systolic Dysfunctionen_US
dc.subject.otherHeart Failureen_US
dc.subject.otherMyocardial Infarctionen_US
dc.subject.otherAldosteroneen_US
dc.titleAldosterone blockade in post‐acute myocardial infarction heart failureen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialitiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, William Beaumont Hospital, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumUniversity of Michigan Medical Center William Beaumont Hospital Cardiovascular Department 1500 East Medical Center Drive Ann Arbor, MI 48109, USAen_US
dc.contributor.affiliationotherLa Paz University Hospital, Madrid Spainen_US
dc.contributor.affiliationotherUniversity Hospital of Ferrara, Ferrara, Italyen_US
dc.contributor.affiliationotherNorthwestern University, Chicago, Illinois, USAen_US
dc.contributor.affiliationotherUniversity Hospital Groningen, Groningen, The Netherlandsen_US
dc.contributor.affiliationotherMonash University, Melbourne, Australiaen_US
dc.contributor.affiliationotherUniversity of Glasgow, Glasgow, Scotlanden_US
dc.identifier.pmid17063946en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90106/1/4960291004_ftp.pdf
dc.identifier.doi10.1002/clc.4960291004en_US
dc.identifier.sourceClinical Cardiologyen_US
dc.identifier.citedreferenceMcMurray JJ, O'Meara E: Treatment of heart failure with spironolactone‐ trial and tribulations. N Engl J Med 2004; 351: 526 – 528en_US
dc.identifier.citedreferenceJuurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 352: 543 – 551en_US
dc.identifier.citedreferenceBanas J, White H, Parkhomenko A, Patni R, Mukherjee R, Zannad F: Favorable outcomes with 25 mg of eplerenone in patients with post‐AMI heart failure: Results from the EPHESUS trial. J Cardiac Fail 2005; 11 (6 suppl):S156en_US
dc.identifier.citedreferenceAbildstrom SZ, Ottesen MM, Rask‐Madsen C, Andersen PK, Rosthoj S, Torp‐Pedersen C, Kober L: Sudden cardiovascular death following myocardial infarction: The importance of left ventricular systolic dysfunction and congestive heart failure. Int J Cardiol 2005; 104: 184 – 189en_US
dc.identifier.citedreferenceSwedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez‐Sendon JL, Nieminen MS, Pierard L, Remme WJ: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115 – 1140en_US
dc.identifier.citedreferenceMoller JE, Brendorp B, Ottesen M, Kober L, Egstrup K, Poulsen SH, Torp‐Pedersen C: Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: Clinical and prognostic implications. Eur J Heart Fail 2003; 5: 811 – 819en_US
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709 – 717en_US
dc.identifier.citedreferencePitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M,for the Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309 – 1321en_US
dc.identifier.citedreferenceSteg PG, Dabbous OH, Feldman LJ,and the Global Registry of Acute Coronary Events Investigators: Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109: 494 – 499en_US
dc.identifier.citedreferenceWu AH, Parsons L, Every NR, Bates ER,for the Second National Registry of Myocardial Infarction: Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI‐2). J Am Coll Cardiol 2002; 40: 1389 – 1394en_US
dc.identifier.citedreferenceHunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005; 112: 1825 – 1852en_US
dc.identifier.citedreferenceAntman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr., Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK,for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction‐ executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588 – 636en_US
dc.identifier.citedreferenceHohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ;and the DINAMIT Investigators: Prophylactic use of an implantable cardioverter‐defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481 – 2488en_US
dc.identifier.citedreferencePitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J,on behalf of the EPHESUS Investigators: Eplerenone reduces mortality 30 days post‐randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425 – 431en_US
dc.identifier.citedreferenceFraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003; 42: 1666 – 1673en_US
dc.identifier.citedreferenceSuzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN: Effects of long‐term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967 – 2972en_US
dc.identifier.citedreferencePerrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gomez AM, Benitah JP: Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004; 110: 776 – 783en_US
dc.identifier.citedreferenceJoffe HV, Adler GK: Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10: 31 – 37en_US
dc.identifier.citedreferenceBrilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809 – 820en_US
dc.identifier.citedreferenceIkeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K: Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin‐1 beta. Eur J Pharmacol 1995; 290: 69 – 73en_US
dc.identifier.citedreferenceDe Angelis N, Fiordaliso F, Latini R: Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002; 34: 1655 – 1665en_US
dc.identifier.citedreferenceSolomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, van de Werf F, Pieper K, Califf RM, Pfeffer MA,for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators: Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581 – 2588en_US
dc.identifier.citedreferenceGoldberg RJ, Spencer FA, Yarzebski J, Lessard D, Gore JM, Alpert JS, Dalen JE: A 25‐year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol 2004; 94: 1373 – 1378en_US
dc.identifier.citedreferenceFonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001; 87: 819 – 822en_US
dc.identifier.citedreferenceWeintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B: Cost‐effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction. Circulation 2005; 111: 1106 – 1113en_US
dc.identifier.citedreferencePitt B: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003; 108: 1790 – 1794en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
4960291004_ftp.pdf
Size:
79.95KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.